|1.||Kownacki, S: 1 article (01/2004)|
|2.||Goodfield, M: 1 article (01/2004)|
|3.||Berth-Jones, J: 1 article (01/2004)|
|4.||Tzaneva, S: 1 article (08/2003)|
|5.||Hönigsmann, H: 1 article (08/2003)|
|6.||Tanew, A: 1 article (08/2003)|
|7.||Williams, H C: 1 article (12/2001)|
|8.||Smith, C H: 1 article (11/2000)|
|9.||Angus, K: 1 article (11/2000)|
|10.||Chinn, S: 1 article (11/2000)|
|1.||Psoriasis (Pustulosis Palmaris et Plantaris)
12/01/2001 - "Exorex for psoriasis: the importance of randomized controlled trials in testing "new" products."
11/01/2000 - "A double blind, randomized, controlled clinical trial to assess the efficacy of a new coal tar preparation (Exorex) in the treatment of chronic, plaque type psoriasis."
01/01/2004 - "Double-blind, randomised, multicentre, parallel group study comparing a 1% coal tar preparation (Exorex) with a 5% coal tar preparation (Alphosyl) in chronic plaque psoriasis."
01/01/2004 - "Exorex lotion is a novel formulation of prepared coal tar indicated for the treatment of psoriasis. "
11/01/2000 - "To determine whether the esterified essential fatty acid complex confers any therapeutic advantage over coal tar alone, patients with chronic plaque psoriasis (n = 20) were entered into a double-blind, randomized, right/left comparison of Exorex, and Exorex without the essential fatty acid component (known hereafter as coal tar control) for 8 weeks. "
|1.||Coal Tar (Estar)
|3.||Essential Fatty Acids